Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

ARS Pharmaceuticals (SPRY) Leases (2021 - 2025)

ARS Pharmaceuticals' Leases history spans 5 years, with the latest figure at $1.4 million for Q3 2025.

  • For Q3 2025, Leases rose 1464.13% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, up 1464.13%, while the annual FY2024 figure was $37000.0, 85.2% down from the prior year.
  • Leases for Q3 2025 was $1.4 million at ARS Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Across five years, Leases topped out at $5.0 million in Q3 2021 and bottomed at $37000.0 in Q4 2024.
  • The 5-year median for Leases is $421500.0 (2022), against an average of $1.3 million.
  • The largest annual shift saw Leases crashed 91.12% in 2023 before it soared 1464.13% in 2025.
  • A 5-year view of Leases shows it stood at $621000.0 in 2021, then decreased by 28.34% to $445000.0 in 2022, then crashed by 43.82% to $250000.0 in 2023, then crashed by 85.2% to $37000.0 in 2024, then surged by 3789.19% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Leases are $1.4 million (Q3 2025), $1.6 million (Q2 2025), and $72000.0 (Q1 2025).